C. Fraga

发表

Investigating rare haematological disorders - A celebration of 10 years of the Sherlock Holmes symposia

Cappellini, U. Jäger, D. Cassiman, 2016 .

Molecular study of congenital erythrocytosis in 70 unrelated patients revealed a potential causal mutation in less than half of the cases (Where is/are the missing gene(s)?)

F. Girodon, C. Bento, C. Rossi, 2013, European journal of haematology.

Carriers of the Complex Allele HFE c.[187C>G;340+4T>C] Have Increased Risk of Iron Overload in São Miguel Island Population (Azores, Portugal)

Claudia C. Branco, R. Cabral, Laura De Fez, 2015, PloS one.

Once- versus twice-daily dosing of eliglustat in adults with Gaucher disease type 1: The Phase 3, randomized, double-blind EDGE trial.

J. Charrow, N. Longo, Xuefan Gu, 2018, Molecular genetics and metabolism.

Management goals for type 1 Gaucher disease: An expert consensus document from the European working group on Gaucher disease.

D. Zafeiriou, P. Iversen, J. Szer, 2018, Blood cells, molecules & diseases.

Management and monitoring recommendations for the use of eliglustat in adults with type 1 Gaucher disease in Europe.

P. Maison-Blanche, C. Niederau, J. Richter, 2017, European journal of internal medicine.

Genetic Basis of Congenital Erythrocytosis: Mutation Update and Online Databases

J. Palmblad, S. Rives, S. Richard, 2014, Human mutation.

Multiple myeloma in elderly patients—a Portuguese multicentric real-life study

H. Coelho, A. Jorge, T. Mendonça, 2019, Annals of Hematology.

Extramedullary Acute Leukemia—Still an Unforeseen Presentation

J. Cabeçadas, C. Fraga, R. Amaral, 2022, Hematology reports.

Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1.

J. Charrow, P. Maison-Blanche, H. Baris, 2018, Blood cells, molecules & diseases.